VCAM1抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using P08968(VCAM1 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P08968(VCAM1 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

VCAM1 (Vascular Cell Adhesion Molecule-1) is a cell surface glycoprotein belonging to the immunoglobulin superfamily, primarily expressed on vascular endothelial cells, macrophages, and certain epithelial cells. It plays a critical role in mediating leukocyte-endothelial adhesion during inflammatory responses by binding to integrins like α4β1 (VLA-4) on immune cells. This interaction facilitates leukocyte recruitment to sites of inflammation, contributing to immune surveillance and pathological processes such as atherosclerosis, rheumatoid arthritis, and cancer metastasis.

VCAM1 antibodies are tools designed to detect or modulate VCAM1 activity. In research, they are widely used to study endothelial activation, inflammation mechanisms, and disease progression. For example, monoclonal antibodies like clone 429 (M/K-2) enable VCAM1 detection in flow cytometry, immunohistochemistry, or Western blotting. In therapeutic contexts, VCAM1-blocking antibodies have been explored to inhibit leukocyte infiltration in inflammatory diseases or disrupt tumor-stroma interactions. However, their clinical translation remains limited, partly due to challenges in balancing efficacy with systemic immune modulation risks.

Elevated soluble VCAM1 levels in serum are also studied as biomarkers for endothelial dysfunction. Overall, VCAM1 antibodies serve as essential reagents for both mechanistic research and potential therapeutic development in inflammation-related pathologies.